For the VEOIBD patients with mutations in the IL10R gene, we and other groups showed that HSCT was the only possible cure for patients with IL-10 signaling deficiency, although it is associated with complications, including graft failure, GVHD and infections. This evidence concerns the gene IL10 and infection.